Analysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $14.50

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus rating of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $14.50.

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating on shares of Agenus in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th.

Agenus Stock Performance

AGEN stock opened at $2.94 on Thursday. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34. The stock has a market capitalization of $99.98 million, a price-to-earnings ratio of -1.38 and a beta of 1.62. The stock’s fifty day moving average is $3.52 and its two-hundred day moving average is $4.12.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing the consensus estimate of $2.63 by ($0.69). The firm had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million. As a group, analysts predict that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Agenus by 1.5% during the third quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after purchasing an additional 36,983 shares during the period. AQR Capital Management LLC grew its position in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Marshall Wace LLP acquired a new position in Agenus during the 2nd quarter valued at about $1,976,000. Bank of America Corp DE increased its stake in Agenus by 110.0% during the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after buying an additional 220,327 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Agenus during the 2nd quarter worth about $906,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.